Medical Device Network

Globally, multiple sclerosis affects over 2.9 million individuals. Credit: Andrzej Rostek / Shutterstock.com. Roche has received CE mark approval of its Elecsys neurofilament light chain (NfL) test, which is designed to detect neuroinflammation in patients with relapsing remitting multiple sclerosis (RRMS). The test aims to enhance disease monitoring by offering a minimally invasive option for clinicians.

Aiva/Zebra at the bedside. Credit: Aiva, Inc/PRNewswire. Zebra Technologies and Aiva Health have collaborated to support hands-free nurse workflows with Aiva’s AI-powered solution. This partnership integrates Aiva’s AI-based Nurse Assistant with Zebra healthcare devices to streamline routine tasks. Discover B2B Marketing That Performs Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

At the American College of Cardiology (ACC) 2026 in New Orleans, retrospective results were presented demonstrating the possibility of using numerous pharmacotherapies, including sodium-glucose cotransporter-2 (SGLT2) inhibitors and colchicine, for patients after the completion of a transcatheter aortic valve replacement (TAVR) procedure. These studies tracked several different patient outcomes from the TriNetX Global Collaborative Network, a multinational database of real-world procedures.

Tense geopolitics continues to define the macroeconomic operating environment for every sector, including medical devices. Navigating policy and regulatory obstacles is a key aspect of doing business and so it becomes more important for OEMs to focus on innovation, making the right investment decisions and supplier partnerships that can support them to win in changing market conditions.

Knight Therapeutics has announced the regulatory submission of Niktimvo (axatilimab) in Brazil for the treatment of chronic graft-versus-host disease (cGvHD), marking another step in the therapy’s geographic expansion beyond its initial approvals in major established markets. In the US, Niktimvo was approved by the FDA in August 2024 for adult and pediatric patients with cGvHD.

Datasets help narrow the gap between everyday clinical care and formal research. Credit: Shutterstock Traditional randomized controlled trials (RCTs) have long been the gold standard for testing new therapies, but they are increasingly strained by today’s rapidly evolving clinical research landscape.

Transforming real-world evidence into usable data involves leveraging AI and machine learning to extract valuable information. Credit: Shutterstock Over the last 20 years, US healthcare has shifted to a value-based system, with payers and healthcare providers being challenged to provide the best care at the lowest cost.

Ypsomed, a medical device company with a focus on self-care solutions, has announced a continued focus on delivery systems such as their portfolio of self-injection devices. This follows previous announcements from Ypsomed regarding strategic changes to their business to better focus on their most successful areas.

Inherited retinal diseases encompass more than 350 genetic mutations and represent a significant unmet clinical need. Opus Genetics’ portfolio approach prioritises indications with well-characterised biology, validated delivery methods, and measurable functional endpoints, enabling streamlined development timelines and capital efficiency. Two of the company’s seven gene therapy assets are already in clinical trials, with additional programs expected to enter the clinic.